SCHEMBL19082663

SCHEMBL19082663

CC(C)(C)NC(=O)CN1[C@@H]2CC[C@H]1C[C@@H](CNC(=O)CC13CC4CC(CC(C4)C1)C3)C2

nearest known ligand 0.74

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CACNA1H O95180 20/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19082620 1.00 CACNA1H (0.74) CACNA1H
SCHEMBL18686512 0.85 CACNA1H (1.00) CACNA1H
SCHEMBL18686511 0.85 CACNA1H (1.00) CACNA1H
SCHEMBL19082637 0.85 CACNA1H (1.00) CACNA1H
SCHEMBL19092157 0.82 CACNA1H (0.78) CACNA1H
SCHEMBL19092176 0.82 CACNA1H (0.78) CACNA1H
SCHEMBL18716650 0.82 CACNA1H (0.78) CACNA1H
SCHEMBL19082662 0.82 CACNA1H (0.78) CACNA1H
SCHEMBL19082654 0.82 CACNA1H (0.78) CACNA1H
SCHEMBL19082639 0.81 CACNA1H (0.77) CACNA1H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9856250-B2 Substituted tropane derivatives TOA EIYO LTD. (JP) 2018-01-02 US disclosed
US-20170190699-A1 SUBSTITUTED TROPANE DERIVATIVES TOA EIYO LTD. (JP) 2017-07-06 US disclosed
US-20170190699-A1 SUBSTITUTED TROPANE DERIVATIVES TOA EIYO LTD. (JP) 2017-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170190699-A1 SUBSTITUTED TROPANE DERIVATIVES CACNA1G, CACNA1H, CACNA1I CACNA1H 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.